Home › Compare › ETTX vs EQR

ETTX vs EQR: Dividend Comparison 2026

ETTX yields 91.32% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ETTX wins by $2.67M in total portfolio value
10 years
ETTX
ETTX
● Live price
91.32%
Share price
$2.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.71M
Annual income
$860,660.59
Full ETTX calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — ETTX vs EQR

📍 ETTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodETTXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ETTX + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ETTX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETTX
Annual income on $10K today (after 15% tax)
$7,762.56/yr
After 10yr DRIP, annual income (after tax)
$731,561.50/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, ETTX beats the other by $726,907.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETTX + EQR for your $10,000?

ETTX: 50%EQR: 50%
100% EQR50/50100% ETTX
Portfolio after 10yr
$1.38M
Annual income
$433,068.10/yr
Blended yield
31.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ETTX
Analyst Ratings
5
Buy
4
Hold
Consensus: Buy
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETTX buys
0
EQR buys
0
No recent congressional trades found for ETTX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricETTXEQR
Forward yield91.32% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$2.71M$47.8K ✓
Annual income after 10y$860,660.59 ✓$5,475.61
Total dividends collected$2.40M$23.0K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: ETTX vs EQR ($10,000, DRIP)

YearETTX PortfolioETTX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$19,832$9,132.42$11,380$679.82+$8.5K → ETTX
2$38,148$16,926.92$13,014$837.25+$25.1K → ETTX
3$71,247$30,428.85$14,961$1,036.20+$56.3K → ETTX
4$129,347$53,112.88$17,297$1,289.22+$112.0K → ETTX
5$228,518$90,117.05$20,121$1,613.15+$208.4K → ETTX
6$393,309$148,794.86$23,561$2,030.84+$369.7K → ETTX
7$660,182$239,341.26$27,783$2,573.54+$632.4K → ETTX
8$1,081,855$375,459.71$33,013$3,284.39+$1.05M → ETTX
9$1,732,607$575,022.24$39,547$4,223.51+$1.69M → ETTX
10$2,714,550$860,660.59$47,791$5,475.61+$2.67M → ETTX

ETTX vs EQR: Complete Analysis 2026

ETTX — Stock

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Full ETTX Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ETTX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETTX vs SCHDETTX vs JEPIETTX vs OETTX vs KOETTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.